Market Snapshot

BSE Sensex: 85712.37 0.52%
BSE 500: 37394.44 0.39%
BSE 200: 11806.46 0.51%
BSE 100: 27394.16 0.56%
BSE MidCap: 46617.8 0.21%
BSE SmallCap: 51093.23 -0.67%
BSE BANKEX: 67018.67 0.86%
BSE IT: 37364.44 0.64%
Nifty 50: 26186.45 0.59%
Nifty 500: 23835.25 0.40%
Nifty 200: 14541.65 0.52%
Nifty 100: 26696.9 0.53%
Nifty Midcap 100: 60594.6 0.49%
Nifty Small 100: 17507.75 -0.57%
Nifty IT: 38703.65 0.90%
Nifty PSU Bank: 8381.75 1.51%

News:

Hindustan Unilever drops as Kw...
Kaynes Technologies drops as b...
Kaynes Technology India Ltd le...
California Software Company Lt...
Bondada Engineering wins Rs 11...

Caplin Point Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

05 Dec 2025 | 03:45 PM

1,963.40

-12.70 (-0.64%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-17.52%

Return (1Y)

Underperformed Nifty 500 by 20.3%
More Volatile

2.61%

Standard Deviation (1Y)

Higher than Nifty 500 by 1.77%
Not so consistent

5/12

Months

underperformed Nifty 500
AxisDirect View

No View

52 Week High-Low

2,641

1,599

News & Announcements

Caplin Point Laboratories consolidated net profit rises 18.08% in the September 2025 quarter
30 days ago

Caplin Point Laboratories consolidated net profit rises 18.08% in the September 2025 quarter

05 - Nov - 2025 12:00 | 30 days ago

Net profit of Caplin Point Laboratories rose 18.08% to Rs 154.45 crore in the quarter ended September 2025 as against Rs 130.80 crore during the previous quarter ended September 2024. Sales rose 10.54% to Rs 534.04 crore in the quarter ended September 2025 as against Rs 483.10 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 534.04 483.10 11

OPM % 35.42 34.08 -

PBDT 219.40 185.22 18

PBT 201.00 168.46 19

NP 154.45 130.80 18

Powered by Capital Market - Live News
Caplin Point Laboratories standalone net profit declines 2.98% in the September 2025 quarter
30 days ago

Caplin Point Laboratories standalone net profit declines 2.98% in the September 2025 quarter

05 - Nov - 2025 12:00 | 30 days ago

Net profit of Caplin Point Laboratories declined 2.98% to Rs 102.59 crore in the quarter ended September 2025 as against Rs 105.74 crore during the previous quarter ended September 2024. Sales declined 15.75% to Rs 175.18 crore in the quarter ended September 2025 as against Rs 207.93 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 175.18 207.93 -16

OPM % 43.30 47.21 -

PBDT 135.02 141.15 -4

PBT 129.00 134.66 -4

NP 102.59 105.74 -3

Powered by Capital Market - Live News
Caplin Point Laboratories to hold board meeting
36 days ago

Caplin Point Laboratories to hold board meeting

30 - Oct - 2025 12:00 | 36 days ago

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 5 November 2025.
Powered by Capital Market - Live News
Caplin Point gets USFDA approval for Nicardipine Hydrochloride injection
42 days ago

Caplin Point gets USFDA approval for Nicardipine Hydrochloride injection

24 - Oct - 2025 12:00 | 42 days ago

The said drug is equivalent to reference listed drug (RLD) from Hikma International Pharmaceuticals LLC.
Nicardipine Hydrochloride in 0.9% Sodium Chloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. According to IQVIA (IMS Health), Nicardipine Hydrochloride in Sodium Chloride injection had US sales of approximately $68 million for the 12-month period ending August 2025.
The company recently acquired the four approved ANDA products, Icatibant Acetate Injection, Paricalcitol Injection, Gatifloxacin Ophthlamic Solution and Ketamine Hydrochloride Injection from third parties.
According to IQVIA (IMS Health), the collective market size for the above products in the US is approximately $121 million for the 12-month period ending August 2025. These products will be introduced into US and other markets in 2026.
Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc.
The company reported an 11.2% year-on-year (YoY) increase in revenue from operations to Rs 510.2 crore and a 20.7% YoY rise in profit after tax (PAT) to Rs 150.8 crore in Q1 FY26.
The scrip declined 1.18% to Rs 2002.40 on the BSE.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Caplin Point Laboratories Ltd has increased by 5.59% since past 3 Months
MF shareholding in Caplin Point Laboratories Ltd has decreased by -7.29% since past 3 Months
FII shareholding in Caplin Point Laboratories Ltd has increased by 75.17% since past 1 Year
MF shareholding in Caplin Point Laboratories Ltd has increased by 10.33% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	534.04	483.10	11
OPM %	35.42	34.08	-
PBDT	219.40	185.22	18
PBT	201.00	168.46	19
NP	154.45	130.80	18

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	175.18	207.93	-16
OPM %	43.30	47.21	-
PBDT	135.02	141.15	-4
PBT	129.00	134.66	-4
NP	102.59	105.74	-3

General Notifications

My Notifications

Research Notifications

Caplin Point Laboratories Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,963.40 -12.70 (-0.64%)

News & Announcements

Price vs Volume

Stock Trivia

Caplin Point Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,963.40

-12.70 (-0.64%)